Intensive Monitoring Scheme of Lidocaine Cataplasms

Qianfoshan Hospital

Status: Enrolling

Conditions: Adverse Reaction to Drug

Treatments: Drug: Lidocaine Cataplasms

Study type: Observational

Funder types: Other

Identifiers

NCT05645302

ZT-DBN-ZDJC-01

Details and patient eligibility

About

In this center, retrospective research methods are used to collect data. Patients who had used Lidocaine Cataplasms at least once were included consecutively. Taking the time when the patient first used Lidocaine Cataplasms as the starting time (the study baseline), collect the demographic characteristics of the patient, the medication scheme of Lidocaine Cataplasms and other information, as well as the medication safety and other information from the first medication to the end of medication or discharge (whichever occurs first).

Enrollment: 200 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• All patients receiving Lidocaine Cataplasms from January 1, 2021 to April 1, 2022.

Exclusion criteria

• Unable to obtain complete medication information.

Trial design

200 participants in 1 patient group

Patients using Lidocaine Cataplasms

Treatment:

Drug: Lidocaine Cataplasms